Login to Your Account

Takeda backs T cell-focused Maverick with $125M, and option to buy

By Michael Fitzhugh
Staff Writer

Wednesday, January 11, 2017

Takeda Pharmaceutical Co. Ltd. is leading a $125 million investment in Maverick Therapeutics Inc., a company founded with initial financing from MPM Capital that is working to improve the utility of T-cell redirection therapy for the treatment of cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription